Characteristics of clinical parameters in patients with diffuse large B-cell lymphoma associated with chromic HIV infection

FAN Hongli; DENG Xuemei; ZHANG Yuying; ZHANG Mi; WANG Jiali; FAN Shangshang

doi:10.3969/j.issn.1007-8134.2024.05.002

Abstract：Objective To analyze the clinical laboratory characteristics of AIDS-related diffuse large B-cell lymphom(DLBCL)patients,so as to provide reference for clinical treatment.Methods Clinical stage,IPI score and pathological subtype of patients diagnosed with AIDS-related diffuse large B-cell lymphoma in our hospital from January 2017 to December 2022 were retrospectively analyzed.Grouped according to different D-dimer(D-D)and Fibrinogen(FIB)levels,and the survival curves of risk were compared in two groups by Log-rank test.Then,compared the levels of D-D and FIB before and after chemotherapy in the survival group and the death group.Results Among the 70 AIDS-related DLBCL patients,males accounted for 77.1％,with a 5-year survival rate of 60.0％.The average survival time of the survivors was significantly longer than that of the deceased(P<0.05),being about three times that of the deceased.In the Ann Arbor clinical staging,the D-D and RDW of patients in stages Ⅰ and Ⅱ were lower than those in stages Ⅲ and Ⅳ,while the HGB and ALB of patients in stages Ⅰ and Ⅱ were higher than those in stages Ⅲ and Ⅳ(P<0.05);in the IPI scoring system,the FIB and D-D levels of patients with IPI scores of 4-5 were higher than those of patients with IPI scores of 0-3,while the HGB and ALB levels of patients with IPI scores of 4-5 were lower than those of patients with IPI scores of 0-3(P<0.05).There was no significant difference in the 5-year PFS between patients with high FIB and D-D plasma levels and those with low levels(P>0.05);after multiple chemotherapies,the FIB content in the plasma of both groups stabilized,while the D-D content in the survivors'plasma showed a downward trend after the second chemotherapy,with a statistically significant difference(P<0.05).Conclusion The clinical status of patients with HIV/AIDS-related diffuse large B-cell lymphoma can be predicted by routine laboratory tests at the early stage of diagnosis.